Choksi Laboratories P/E Ratio
Current P/E Ratio
50.24
High Valuation
Very High - High growth expectations or significantly overvalued
Choksi Laboratories (CHOKSILA) P/E ratio is 50.24 (High), EPS (TTM) ₹2.19, current price ₹132.60 on BSE — Very High - High growth expectations or significantly overvalued. Analyse CHOKSILA FII DII holdings to track promoter, FII and institutional holdings.
Current Valuation Metrics
P/E Ratio
50.24
Current Price
₹132.60
EPS (TTM)
₹2.19
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
67.8
Sector Median
44.49
Sector Rank
#11 of 56
Sector Percentile
19.6%
CHOKSILA P/E Ratio — Valuation Signal & Historical Context
Choksi Laboratories P/E 50.24 — signal: Overvalued. Browse CHOKSILA cash flow statement for revenue, profit, balance sheet and cash flow data.
- Stock appears overvalued with PE of 50.24, suggesting caution for new investments
- Trading at discount to sector average PE of 67.8
CHOKSILA vs Healthcare Services Peers — P/E Ratio Comparison
Choksi Laboratories P/E 50.24 vs Healthcare Services average 67.8, median 44.49 — range 7.98–460.81.
Sector Average
67.8
Sector Median
44.49
Lowest P/E
7.98
Highest P/E
460.81
Companies
56
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Star Imaging And Path Lab | STARIMAGIN | 7.98 | ₹125 | Low |
| Shanmuga Hospital | SHANMUGA | 12.91 | ₹54 | Low |
| Nidan Labs & Healthcare | NIDAN | 13.47 | ₹20 | Low |
| Deccan Health Care | DECCAN | 14.18 | ₹32 | Low |
| One Global Service Provi… | ONEGLOBAL | 14.84 | ₹920 | Low |
| Abate AS Industries | ABATEAS | 14.93 | ₹162 | Low |
| Invicta Diagnostic | INVICTA | 17.24 | ₹80 | Moderate |
| 3B BlackBio DX | 3BBLACKBIO | 17.7 | ₹1,061 | Moderate |
| Indraprastha Medical Cor… | INDRAMEDCO | 17.93 | ₹3,334 | Moderate |
| Dr Lalchandani Labs | DLCL | 19.85 | ₹8 | Moderate |